InD application for Arvinas candidate therapy ARV-471 obtains FDA approval

today, Pharmaceutical Sincon partner Arvinas(http:// announcedthat its application for inDD for its candidate therapy ARV-471 was approved by theFDA(http://ARV-471 is an oral estrogen receptor (ER) PROTAC protein degradation agent used to treat patients with late-stage or metastatic ER-HER2-breast cancerPhase 1 clinical trials are scheduled to begin in the third quarter of 2019This is the company's second proTRAC treatment to enter the clinicaltrial(http://Arvinas PROTAC protein degradation agents use the body's natural protein recovery system to degrade disease-causing proteinsPROTAC proprotein degradation agents are able to raise E3 connecting enzymes to label the target proteins ubiquitin, which leads to the degradation of these proteins by proteasesafter the target protein is degraded, the PROTAC protein degradation agent is released and can be reused for re-use to degrade other target proteinsARV-471 is a PROTAC protein degradation agent specifically designed for targeting and degradation of ERThe first phase of the trial will assess the safety, tolerability and pharmacokinetic characteristics of ARV-471, and measure anti-tumor activity and pharmacodynamic indicators as secondary evaluation indicatorsin preclinical studies, ARV-471 showed near-complete ER degradation in tumor cellsWhen prescribed as a single-drug therapy in multiple ER-driven xenotransplant models or in combination with CDK4/6 inhibitors, the tumor is significantly reduced and anti-tumor activity is shown to be superior compared to standard therapy (fulvestrant) According to Arvinas, the differentiated pharmacological properties of ARV-471 promise meaningful clinical benefits for patients